Who Generates More Revenue? HUTCHMED (China) Limited or Travere Therapeutics, Inc.

HUTCHMED's Revenue Soars Past Travere's in 2023

__timestampHUTCHMED (China) LimitedTravere Therapeutics, Inc.
Wednesday, January 1, 20149181300028203205
Thursday, January 1, 201517820300099892000
Friday, January 1, 2016216080000133591000
Sunday, January 1, 2017241203000154937000
Monday, January 1, 2018214109000164246000
Tuesday, January 1, 2019204890000175338000
Wednesday, January 1, 2020227976000198321000
Friday, January 1, 2021356128000227490000
Saturday, January 1, 2022426409000212018000
Sunday, January 1, 2023837999000145238000
Loading chart...

Cracking the code

Revenue Race: HUTCHMED vs. Travere Therapeutics

In the dynamic world of pharmaceuticals, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, HUTCHMED (China) Limited and Travere Therapeutics, Inc. have been pivotal players in this arena. From 2014 to 2023, HUTCHMED consistently outperformed Travere in revenue generation, with a notable surge in 2023, where it nearly quadrupled its revenue compared to 2014. This represents a staggering 813% increase over the period. In contrast, Travere Therapeutics saw a more modest growth, with its revenue increasing by approximately 415% during the same timeframe. The data highlights HUTCHMED's strategic advancements and market expansion, particularly in recent years. As the pharmaceutical industry continues to evolve, these companies' financial trajectories offer valuable insights into their competitive strategies and future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025